In terms of OS, CBX3 methylation is a risk factor for BRCA, KIRC and STAD patients, but a protective factor for KIRP, LAML, UVM, SARC, READ, LUAD, LIHC, and LGG patients (Figure 13). This evidence concerns the gene CBX3 and gastric adenocarcinoma.